of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Chief Legal Officer — Mr. Nilay Patel: The Chief Legal Officer position was eliminated, resulting in the departure of Mr. Nilay Patel.

Annual board election and routine administrative appointments.

Executive Vice President and Chief Medical Officer — Matthew N. Brams: The trial period for Mr. Brams' full-time employment was extended.

Regulation FD Disclosure. On June 2, 2026, Cingulate Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) for its New Drug Application for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”). A copy of the press release is attached hereto as Exhibit 99.1 . The information included in this

Other Events. On June 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301. The FDA identified specific Chemistry, Manufacturing and Controls information requests in the CRL and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. The Company expects a prompt resubmission to FDA of the remaining requested information addressing issues raised in the CRL.

Director — Jeff Ervin and Jay Roberts: The current Class II directors, Jeff Ervin and Jay Roberts, will not seek re-election to reduce the size of the Board.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Director — Zhanpeng “Frederick” Jiang: Mr. Zhanpeng “Frederick” Jiang was appointed as a member of the Board of Directors and joined multiple committees.

Entry Into a Material Definitive Agreement. On March 24, 2026, Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners, as sales agent (“A.G.P.”), pursuant to which the Company may offer and sell, from time to time through A.G.P., shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $100,000,000 (the “Placement Shares”). The offer and sale of the Placement…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Other Events. On February 13, 2026, the Company completed the second and final portion of the Private Placement for gross proceeds of an additional $5.5 million. The aggregate gross proceeds from the Private Placement, including the initial closing, totaled approximately $12.0 million.

Unregistered Sales of Equity Securities On February 6, 2026, Cingulate Inc. (the “ Company ”) issued 25,786 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a value of $6.16 per share to a lender in exchange for a portion of the debt owed to such lender. Such issuance was exempt from registration under 3(a)(9) of the Securities Act.

Director — Jeff Hargroves: Appointment of Jeff Hargroves as a Class I director and member of multiple board committees.

Regulation FD Disclosure. On February 17, 2026, the Company announced the second and final closing of the Private Placement for gross proceeds of an additional $5.5 million. The aggregate gross proceeds from the Private Placement, including the initial closing, totaled approximately $12.0 million. The information included in this

Unregistered Sales of Equity Securities From January 6, 2026 through February 5, 2026, Cingulate Inc. (the “ Company ”) issued the securities described below in transactions that were not registered under the Securities Act of 1933, as amended (the “ Securities Act ”). On January 6, 2026, the Company issued 68,965 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a value of $4.35 per share to a lender in exchange for a portion of the debt owed to such le…

Other Events. On February 6, 2026, the Company completed a portion of the private placement previously announced in our Current Report on Form 8-K, dated January 28, 2026, for gross proceeds of $6.5 million. The Company expects to close the remaining $5.5 million of the private placement as soon as practicable, following the anticipated completion of the closing conditions. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this repor…

Unregistered Sales of Equity Securities The information under

Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On January 27, 2026, Cingulate Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with the several purchasers named therein (the “ Purchasers ”), including certain officers, directors and other affiliates of the Company, for the private placement (the “ Private Placement ”) of: (i) 2,147,471 shares of the Company’s common stock, par value $0.0001 per share…

Other Events. On January 12, 2026, Cingulate Inc. (the “Company”) increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated January 3, 2023, from $23,536,658 to $31,936,658 and filed a prospectus supplement (the “Current Prospectus Supplement”) under the Sales Agreement for an aggregate of $8,840,0…

Unregistered Sales of Equity Securities From November 21, 2025 through January 2, 2026, Cingulate Inc. (the “Company”) issued the securities described below in transactions that were not registered under the Securities Act of 1933, as amended (the “Securities Act”). On November 21, 2025, the Company issued 73,746 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a value of $3.39 per share to a lender in exchange for a portion of the debt owed to such lende…

null — Dr. Schaffer: The Employment Agreement for Dr. Schaffer was amended, including changes to his base salary and terms of termination.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. On November 7, 2025, Cingulate, Inc. (the “Company”), entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Avondale Capital, LLC, a Utah limited liability company (“Lender”), pursuant to which the Company issued and sold to Lender an unsecured promissory note (the “Note”) in the amount of $6,570,000 (the “Principal Amount”). The Principal Amount includes an original issue discount of $540,000. In exchange for the Note, Lender…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent required by